<DOC>
	<DOCNO>NCT00754325</DOCNO>
	<brief_summary>The purpose study find effect combination fulvestrant ( Faslodex ) dasatinib ( Sprycel ) advance breast cancer compare fulvestrant alone .</brief_summary>
	<brief_title>Randomized Trial Fulvestrant With Without Dasatinib Men Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With Aromatase Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BristolMyers Squibb ( BMS ) clinical trial participation , please visit www.BMSStudyConnect.com . Histologically confirm hormone receptor positive ( HR+ ) [ ( estrogen receptor ( ER+ ) and/or progesterone receptor ( PgR+ ) ] breast cancer accord immunohistochemistry ( IHC ) Measureable evaluableonly disease human epidermal growth factor receptor 2+ ( HER2+ ) HER2 breast cancer Males females â‰¥18 year age Females post menopausal surgically sterile Recurrent progressive advance breast cancer ( locallyadvanced metastatic ) , progress : ( ) within 12 month completion adjuvant Aromatase Inhibitor ( AI ) treatment OR ( b ) AI treatment advance setting ( metastatic therapy ) Pregnant breast feed &gt; 1 chemotherapy regimen advance disease Pleural pericardial effusion Serious cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>